bioRxivBiophysicsPreprint
Buffered sweat microfluidics with AI-enabled translation for clinically actionable blood urea estimation and renal risk stratification
Jiahao ZhangiD, Zhengquan Shen, Ming Xu, Yukun GeiD, Xi Ren, Genlin Liu, Xiuwei Zhang, Simian FuiD, C Yang, Minghui Long, Shu Li, Gaozhi P MoiD, Yi GongiD, Nan LiiD, Peiyu MaiD, Zhiyong PengiD, Yunlong ZhaoiD
Abstract
Kidney-function assessment relies on blood urea as a clinically informative metabolic marker; however, its dependence on venipuncture and centralised laboratory testing limits high-frequency monitoring and delays timely clinical intervention. Here, we report an integrated platform combining a wearable buffered microfluidic patch with a physiology-informed, data-driven calibration framework for real-time, non-invasive estimation of blood urea from microlitre-scale sweat volumes (4.79 L). By precisely regulating the release kinetics of internal buffer salts, the device stabilises the local reaction microenvironment, mitigating variability in sweat pH and flow to ensure reproducible measurement. The resulting signals are processed through an artificial intelligence (AI)-enabled analysis pipeline that integrates sweat urea with patient-specific physiological information to generate clinically interpretable outputs. In multicentre studies, sweat urea shows a strong association with blood urea across diverse cohorts, but with nonlinear and time-lagged relationships that limit direct use. The AI-enabled calibration model compensates for these effects, enabling high-fidelity estimation of blood urea (r = 0.945 versus gold-standard measurements) at clinically relevant concordance levels. The platform further identifies kidney injury with 89.1% accuracy and stratifies disease severity with 83.2% accuracy. Notably, these results demonstrate that the integration of physicochemical stabilisation and AI-enabled data-driven translation establishes sweat as a clinically actionable surrogate for renal monitoring, supporting population-level estimation and highlighting the potential for personalised longitudinal assessment, and enabling a scalable, non-invasive strategy for high-frequency kidney disease management.
- organism: human
- assay: imaging
- assay: metabolomics
- research focus: drug response / drug discovery
- approach: deep learning
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Body Fluid Estimation during Standard Ultrafiltration in Chronic Kidney Disease
Rammah M. Abohtyra, Omar Ali Beg·Proceedings of the ... American Control Conference/Proceedings of the American Control ConferencePeer-reviewed·Jul 8, 2025
- Wearable facemask-attached disposable printed sensor arrays for point-of-need monitoring of ammonia in breath
Giandrin Barandun, Abdulkadir Sanli, … Firat Güder·PNAS NexusPeer-reviewed·Mar 27, 2025
- Prediction of Acute Kidney Injury with a Machine Learning Algorithm using Electronic Health Record Data
Hamid Mohamadlou, Anna Lynn-Palevsky, … Ritankar Das·Canadian Journal of Kidney Health and DiseasePeer-reviewed·Jan 1, 2018
- Assessment of urinary exosome NHE3 as a biomarker of acute kidney injury
Yanting Yu, Zhiyun Ren, … Xiaoyan Wang·bioRxiv·Jun 12, 2022
- Design and Development of Point of Care Test and Optical Reader for Early Screening of Kidney Related Disorder
P. Shivhare, S. Mohla, … R. Srivastava·bioRxiv·Jul 1, 2020
- Cytokines in the Urine of AKI patients regulate TP53 and SIRT1 and can be used as biomarkers for the early detection of AKI
Lars Erichsen, Chantelle Thimm, … James Adjaye·bioRxiv·Jan 20, 2023